Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma

By Kivela T.   Suciu S.   Hansson J.   Kruit W.H.J.   Vuoristo M.-S.   Kloke O.   Gore M.   Hahka-Kemppinen M.   Parvinen L.-M.   Kumpulainen E.   Humblet Y.   Pyrhonen S.  

European Journal of Cancer, Vol. 39, Iss. 8, 2003-05 ,pp. : 1115-1120

Elsevier

Access to resources Recommend Favorite

A Phase II Study of Dacarbazine, Cisplatin, Interferon- and High-dose Interleukin-2 in 'Poor-risk' Metastatic Melanoma

By Proebstle T.M.   Scheibenbogen C.   Sterry W.   Keilholz U.  

European Journal of Cancer, Vol. 32, Iss. 9, 1996-08 ,pp. : 1530-1533

Elsevier

Access to resources Recommend Favorite

A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma

By Varker Kimberly   Biber Jennifer   Kefauver Cheryl   Jensen Rhonda   Lehman Amy   Young Donn   Wu Haifeng   Lesinski Gregory   Kendra Kari   Chen Helen   Walker Michael   Carson III William  

Annals of Surgical Oncology, Vol. 14, Iss. 8, 2007-08 ,pp. : 2367-2376

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of cisplatin, 5-fluorouracil, and interferon- -2B as first line treatment of advanced urothelial cancer

By Bazarbashi S.   Pai C.   Raja M.A.   Rahal M.   Ezzat A.   Hanash K.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 3, 2003-05 ,pp. : 185-189

Elsevier

Access to resources Recommend Favorite

Phase II Trial of N-(phosphonacetyl)-l-aspartate (PALA), 5-Fluorouracil and Recombinant Interferon- -2b in Patients with Advanced Gastric Carcinoma

By Wadler S.   Gleissner B.   Hilgenfeld R.U.   Thiel E.   Haynes H.   Kaleya R.   Rozenblit A.   Kreuser E.-D.  

European Journal of Cancer, Vol. 32, Iss. 7, 1996-06 ,pp. : 1254-1256

Elsevier

Access to resources Recommend Favorite